icon-folder.gif   Conference Reports for NATAP  
 
  66th Annual Meeting of the
American Association for the
Study of Liver Diseases
Boston, MA Nov 13-17 2015
Back grey_arrow_rt.gif
 
 
 
RUBY-I: Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir ± Ribavirin in Non-Cirrhotic HCV Genotype 1-Infected Patients With Severe Renal Impairment or End-Stage Renal Disease
 
 
  Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco
 
Paul J Pockros1, K Rajender Reddy2, Parvez S Mantry3, Eric Cohen4, Michael Bennett 5, Mark S Sulkowski6, David Bernstein7, Daniel E Cohen4, Nancy S Shulman4, Deli Wang4, Amit Khatri4, Manal Abunimeh4, Thomas Podsadecki4, Eric Lawitz8
 
1Scripps Clinic and Scripps Translational Science Institute, La Jolla, California, United States; 2University of Pennsylvania, Philadelphia, Pennsylvania, United States; 3The Liver Insti tute at Methodist Dallas, Dallas, Texas, United States; 4AbbVie Inc., North Chicago, Illinois, United States; 5Medical Associates Research Group, San Diego, California, United States; 6Johns Hopkins University, Baltimore, Maryland, United States; 7North Shore University Hospital, Manhasset, New York, United States; 8The Texas Liver Institute, University of Texas Health Science Center, San Antonio, Texas, United States

AASLD1.gif

AASLD2.gif

AASLD3.gif

AASLD4.gif

AASLD5.gif

AASLD6.gif

AASLD7.gif

AASLD8.gif

AASLD9.gif

AASLD10.gif

AASLD11.gif

AASLD12.gif